Cost of home care at hospital level treatment vs in-hospital treatment in complicated urinary tract infection
##plugins.themes.bootstrap3.article.details##
Objective: To evaluate the difference costs considering a third-party payer perspective in patients with complicated urinary tract infection between a hospital-level home care service and standard hospitalization.
Methods: Retrospective cohort study, retrieving medical records of patients with complicated urinary tract infection diagnosis treated at a fourth-level hospital, from January 2017 to May 2020. A linear regression model was obtained to evaluate cost per day attention determinants.
Results: 239 patients were included in the hospitalized group and 68 in the hospital-level home care group. The in-hospital cohort was older (median 71 vs 59 years, p=0.002). There were no differences in 30-day mortality rate (2.1% vs 5.9%, p=0.114) or total costs of attention (Colombian pesos (COP) 8767141 vs 9558334, p= 0.112). A longer clinical attention (median 17 vs 12 days, p<0.001) and a lower cost/day were found in patients hospitalized at home (COP 756100 vs 554685, p<0.001).The following factors were associated with increased cost/day: hospital-level home care (COP –209155, p=0.01), Charlson index ≥6 (COP 26250, p=0.001), surgical procedures (COP 368157, p<0.001), Intensive Care Unit requirement (COP 373927, p<0.001), subsidized regimen (COP 209156, p=0.013), staphylococcus isolation (COP 1252473, p<0.001) and carbapenemase-producing germs (COP 629319, p<0.001).
Conclusions: This study suggests that cost/day attention for patients with complicated urinary tract infection is lower in patient treated by a hospital-level home service. However, the total costs are similar. Additionally, hospital-level home service is secure.
Urinary tract infections, cost and cost analysis, Home care services, Health Care Economics and Organizations, ColombiaInfecções Urinárias, Custos e Análise de Custo, Serviços de Assistência Domiciliar, Economia e Organizações de Saúde, ColombiaInfecciones urinarias, costo y análisis de costo, Servicios de Atención de Salud a Domicilio, Economía en Atención de Salud y Organizaciones, Colombia
2. Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, et al. The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention. Urol Int. 2018;
3. Vallejo-Torres L, Pujol M, Shaw E, Wiegand I, Vigo JM, Stoddart M, et al. Cost of hospitalised patients due to complicated urinary tract infections: A retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: The COMBACTE-MAGNET, RESCUING study. BMJ Open. 2018;8(4):1–9.
4. Salvatierra-González R. Costo de la infección nosocomial en nueve países de América Latina. Organ Panam la salud. 2003;
5. Guarnizo JF, Parra García SV, Muñoz DA, Ramos JA. Costos directos de las infecciones del tracto urinario asociado al uso de dispositivo vesical en los pacientes del Hospital Universitario Hernando Moncaleano Perdomo de Neiva durante el año 2013 y el primer semestre del 2014. RFS Rev Fac Salud. 2016;
6. Rodríguez-Burbano, Lady, De La Hoz FP, Leal-Castro AL. Costo de infección de vías urinarias asociada a sonda vesical en un hospital universitario de Santander, Colombia. Rev Salud Publica. 2016;
7. Matthews PC, Conlon CP, Berendt AR, Kayley J, Jefferies L, Atkins BL, et al. Outpatient parenteral antimicrobial therapy (OPAT): Is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years. J Antimicrob Chemother. 2007;
8. Gonçalves-Bradley DC, Iliffe S, Doll HA, Broad J, Gladman J, Langhorne P, et al. Early discharge hospital at home. Cochrane Database Syst Rev. 2017;2017(6).
9. Donnelly M, Power M, Russell M, Fullerton K. Randomized Controlled Trial of an Early Discharge Rehabilitation Service: The Belfast Community Stroke Trial. Stroke. 2004;
10. Beech R, Rudd AG, Tilling K, Wolfe CDA. Economic consequences of early inpatient discharge to community-based rehabilitation for stroke in an inner-London teaching hospital. Stroke. 1999;
11. Anderson C, Mhurchu CN, Rubenach S, Clark M, Spencer C, Winsor A. Home or hospital for stroke Rehabilitation? Results of a randomized controlled trial : II: cost minimization analysis at 6 months. Stroke. 2000 May;31(5):1032–7.
12. Zarate V. Evaluaciones económicas en salud: Conceptos básicos y clasificación. Rev Med Chil. 2010;
13. Benhumea AM, Villalobos JE, Jaimes PA, Benhumea NH, Manzur MÁ, Ortiz A. Estructura, sistemas y análisis de costos de la atención médica hospitalaria. Med e Investig. 2015 Aug 1;3.
14. Mirón-Rubio M, González-Ramallo V, Estrada-Cuxart O, Sanroma-Mendizábal P, Segado-Soriano A, Mujal-Martínez A, et al. Intravenous antimicrobial therapy in the hospital-at-home setting: Data from the Spanish Outpatient Parenteral Antimicrobial Therapy Registry. Future Microbiol. 2016;11(3):375–90.
15. Levine DM, Ouchi K, Blanchfield B, Saenz A, Burke K, Paz M, et al. Hospital-level care at home for acutely ill adults a randomized controlled trial. Ann Intern Med. 2020;172(2):77–85.
16. Yong C, Fisher DA, Sklar GE, Li SC. A cost analysis of Outpatient Parenteral Antibiotic Therapy (OPAT): an Asian perspective. Int J Antimicrob Agents. 2009;
17. Zilberberg MD, Nathanson BH, Sulham K, Shorr AF. Descriptive Epidemiology and Outcomes of Hospitalizations With Complicated Urinary Tract Infections in the United States, 2018. Open forum Infect Dis. 2022 Jan;9(1):ofab591.
18. Skwarska E, Cohen G, Skwarski KM, Lamb C, Bushell D, Parker S, et al. Randomised controlled trial of supported discharge in patients with exacerbations of chronic obstructive pulmonary disease. Thorax. 2000;
19. Cotton MM, Bucknall CE, Dagg KD, Johnson MK, MacGregor G, Stewart C, et al. Early discharge for patients with exacerbations of chronic obstructive pulmonary disease: A randomised controlled trial. Thorax. 2000;
20. Cardwell SM, Crandon JL, Nicolau DP, McClure MH, Nailor MD. Epidemiology and economics of adult patients hospitalized with urinary tract infections. Hosp Pract (1995). 2016;44(1):33–40.
21. Vallejo-Torres L, Pujol M, Shaw E, Wiegand I, Vigo JM, Stoddart M, et al. Cost of hospitalised patients due to complicated urinary tract infections: A retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: The COMBACTE-MAGNET, RESCUING study. BMJ Open. 2018;
22. Mendoza-Ruiz De Zuazu H, Casas-Arrate J, Martínez-Martínez C, De La Maza I, Regalado De Los Cobos J, Cía-Ruiz JM. Antibioterapia intravenosa en domicilio. Estudio de 515 casos. Enferm Infecc Microbiol Clin [Internet]. 2005;23(7):396–401. Available from: http://dx.doi.org/10.1157/13078797
23. Quintens C, Steffens E, Jacobs K, Schuermans A, Van Eldere J, Lagrou K, et al. Efficacy and safety of a Belgian tertiary care outpatient parenteral antimicrobial therapy (OPAT) program. Infection [Internet]. 2020;(0123456789). Available from: https://doi.org/10.1007/s15010-020-01398-4
24. Trad MA, Zhong LH, Llorin RM, Tan SY, Chan M, Archuleta S, et al. Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections. J Chemother. 2017;29(1):25–9.
25. Ferry SA, Holm SE, Stenlund H, Lundholm R, Monsen TJ. Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: The LUTIW project. Scand J Prim Health Care. 2007;
26. Wolter JM, Cagney RA, McCormack JG. A randomised trial of home vs hospital intravenous antibiotic therapy in adults with infectious diseases. J Infect. 2004;48(3):263–8.
This work is licensed under a Creative Commons Attribution 4.0 International License.